PeproMene Bio Inc., an Irvine-based biotechnology company with a blood cancer immunotherapy licensed from City of Hope, has received $40.2 million in investor funding.
The Series B round by 17 investors was announced in a June 11 filing with the Securities and Exchange Commission.
PeproMene, a pre-clinical firm founded in 2016, employs a chimeric antigen receptor T-cell (CAR-T) therapy to treat non-Hodgkin lymphomas developed by Dr. Larry Kwak, director of the Toni Stephenson Lymphoma Center at City of Hope National Medical Center in Duarte.
Kwak also serves as chair of the scientific advisory board at PeproMene Bio. His former lab at the National Cancer Institute pioneered a cancer vaccine for B-cell malignancies. In 2010, Time magazine named the award-winning scientist among the world’s 100 most influential people.
He is joined on the board by Dr. Hong Qin, a principal researcher in immune-oncology who works with Kwak at the lymphoma center at City of Hope.
In September, PeproMene Bio raised $4 million in a series A round. Its BAFF-R CAR-T treatment for B-cell cancers is being developed at the Duarte hospital.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
You May Also Like
- City of Hope Receives $3.7M to Conduct Stem Cell Research on Brain Cancer
- City of Hope Wins $13 Million Grant to Fight Aggressive Brain Cancer
- City of Hope Lands Nearly $6M Grant for Stem Cell Study for Sickle Cell Disease
- Biotech Mogul Patrick Soon-Shiong to Launch Nant IPO
- Family of City of Hope Dynamo Gives $1 Million to Spur CART Cancer Therapy
- Kite Wins Approval to Market Cancer Therapy in Europe
- Gilead Sciences and Kite Pharma Acquire Cell Design Labs
- UCLA and City of Hope Receive $2.8 Million in Grants for Stem Cell Research